36 filings
Page 2 of 2
8-K
oqs 1bafofw5kimz
26 Apr 22
Compass Therapeutics Announces Appointment of Two New Directors to its Board
8:01am
8-K
f968fn5
25 Feb 22
Departure of Directors or Certain Officers
5:04pm
8-K
gxv8ywoqmyy5
20 Jan 22
Other Events
8:30am
8-K
a6sfndh qe
21 Dec 21
Departure of Directors or Certain Officers
5:07pm
8-K
dnue4roy
3 Nov 21
Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
5:29pm
8-K
rnqcxlm82 yp27x
1 Nov 21
Results of Operations and Financial Condition
4:05pm
8-K
aclirz0 hofwlhi
8 Oct 21
Other Events
12:01pm
8-K/A
slq2ss5d8upcvvl9
5 Aug 21
Independent Auditor’s Report
12:00am
8-K
l5s bhb6f9mr
30 Jun 21
Entry into a Material Definitive Agreement
1:42pm
8-K
1pw2tci 550g
4 Jun 21
Submission of Matters to a Vote of Security Holders
7:57am
8-K
od3oq
13 May 21
To Obtain Global Rights to TR009, A Novel bispecific antibody and Inhibitor of the Notch Pathway Targeting DLL4 and VEGF-A
2:00pm
8-K
snzwq khndoge9e4b
19 Apr 21
Departure of Directors or Certain Officers
4:00pm
8-K
w568zzx voa
17 Dec 20
Entry into a Material Definitive Agreement
5:02pm
8-K
q5asmc
15 Sep 20
Compass Therapeutics, Inc. Provides Corporate Update
10:28am
8-K/A
s16crq8r pkvg49pjptu
31 Jul 20
Completion of Acquisition or Disposition of Assets
5:26pm
8-K
wxm212lmlk lt
23 Jun 20
Entry into a Material Definitive Agreement
5:15pm